Representation of African-Americans, Hispanics, and Whites in National Cancer Institute Cancer Treatment Trials
Hugo A. Tejeda(Rutgers, The State University of New Jersey), Otis W. Brawley(American Cancer Society), Leslie G. Ford, Juliet High(National Cancer Institute), S. B. Green(National Cancer Institute), Edward L. Trimble(Memorial Sloan Kettering Cancer Center), Michael Friedman(United States Food and Drug Administration), Richard S. Ungerleider(Theradex Oncology (United States))
Cited by 275
Related Papers
Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia.
|Journal of Clinical Oncology|1996|914
How Sociodemographics, Presence of Oncology Specialists, and Hospital Cancer Programs Affect Accrual to Cancer Treatment Trials
|Journal of Clinical Oncology|2002|531
Effect of Surgeon Specialty on Processes of Care and Outcomes for Ovarian Cancer Patients
|JNCI Journal of the National Cancer Institute|2006|415
Protein-associated deoxyribonucleic acid strand breaks in L1210 cells treated with the deoxyribonucleic acid intercalating agents 4'-(9-acridinylamino)methanesulfon-m-anisidide and adriamycin
|Biochemistry|1981|375
Representation of older patients in cancer treatment trials
|Cancer|1994|349